Press Release

HeartFlow Names New General Counsel to Executive Team

REDWOOD CITY, Calif. – Dec. 23, 2014 – HeartFlow Inc., a pioneer in personalized medical technology for cardiovascular disease, has appointed Noemi C. (“Nicky”) Espinosa, as general counsel. Espinosa brings to HeartFlow 30 years of experience as both a business executive and outside counsel, representing medical device, life science and high tech companies.

“Nicky’s extensive experience and understanding of the complexities of healthcare and business make her an ideal addition to the HeartFlow team,” said John H. Stevens, M.D., chairman and CEO of HeartFlow. “Her knowledge of the legal, regulatory and business hurdles both small and large companies face will be extremely valuable as we commercialize our HeartFlow FFRCT® technology.”

Just prior to joining HeartFlow, Espinosa served as vice president of legal operations and assistant general counsel for Intuitive Surgical in Sunnyvale, Calif. She also served as the vice president of intellectual property for Illumina, Inc., in San Diego. Espinosa also spent more than 20 years in private practice as a litigation partner in the Silicon Valley offices of three major national law firms: Brobeck, Phleger & Harrison LLP, Dewey Ballantine LLP, and Dechert LLP. While in private practice, she advised and represented a variety of emerging growth and publicly held life science and technology companies.

Espinosa received her Bachelor of Science degree in chemical engineering from San Jose State University, and a juris doctorate degree from the University of California, Hastings College of the Law.

About HeartFlow Inc.

HeartFlow Inc. is a personalized medical technology company dedicated to transforming the way cardiovascular disease is managed. Committed to improving outcomes, reducing costs and creating a better patient experience, HeartFlow’s goal is to provide healthcare professionals with actionable knowledge about each patient by combining best-in-class, non-invasive healthcare imaging with advanced, computational fluid dynamics technology and the insights of big data. HeartFlow’s non-invasive FFRCT technology helps physicians diagnose coronary artery disease and provides them with information they need to manage each patient. For more information visit www.heartflow.com.


Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!

オンライン提出フォームから研究助成金を申請してください。

HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。

ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.

さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please use our online submission form on the Clinical Research Page to apply for research grants.

Thank you for your interest!

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.